Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
165,547,872
-
Total 13F shares
-
32,308,752
-
Share change
-
+3,107,822
-
Total reported value
-
$738,633,935
-
Put/Call ratio
-
9.6%
-
Price per share
-
$22.86
-
Number of holders
-
139
-
Value change
-
+$66,042,910
-
Number of buys
-
85
-
Number of sells
-
62
Institutional Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q2 2018
As of 30 Jun 2018,
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) was held by
139 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
32,308,752 shares.
The largest 10 holders included
FMR LLC, PRICE T ROWE ASSOCIATES INC /MD/, BlackRock Inc., VANGUARD GROUP INC, PERCEPTIVE ADVISORS LLC, STATE STREET CORP, RENAISSANCE TECHNOLOGIES LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Aquilo Capital Management, LLC, and FIL Ltd.
This page lists
139
institutional shareholders reporting positions in this security
for the Q2 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.